-
Trautec Medical Raises RMB200m in Series A Financing for Recombinant Collagen R&D
•
China-based Jiangsu Trautec Medical Technology Co., Ltd. has reportedly raised nearly RMB200 million (USD205.3 million) in a Series A financing round. The round was led by Shiseido’s Ziyue Fund, with participation from Hua Fang Investment, CDH Wealth Management, and Holley Pharma. The proceeds will be directed towards investments in technology…
-
Zhaoke Ophthalmology Enrolls First Patient in ZKY001 Phase II TPRK Study
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) announced the enrollment of the first patient in a Phase II clinical study for its ZKY001 in transepithelial photorefractive keratectomy (TPRK), a surgical procedure to treat myopia. ZKY001 is based on a peptide composed of seven amino…
-
Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery
•
Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of a USD95 million Series D financing round following Series D2 funding. The round was led by Saudi Aramco’s Prosperity7 Ventures. The proceeds will be used to advance its in-house developed product pipeline and accelerate pivotal…
-
LianBio Completes Enrollment for Mavacamten Phase III Trial in oHCM
•
China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III EXPLORER-CN clinical trial, assessing mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Drug BackgroundMavacamten, discovered by MyoKardia Inc. (Nasdaq: MYOK), is a first-in-class small-molecule drug that reversibly binds to myosin. It targets the…
-
Huadong Medicine to Acquire 60% Stake in Wuhu Huaren for RMB 396 Million
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, is set to acquire a 60% stake in compatriot firm Wuhu Huaren Science and Technology Co., Ltd. The deal involves a consideration of RMB 396 million (USD 58.7 million), consisting of RMB 180…
-
Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject enrollment and first vaccination in an immuno-bridging study for its recombinant HPV 9-valent vaccine, REC603. The study targets younger-age groups and aims to compare the immunogenicity between REC603 and Gardasil 9. Meanwhile, follow-up on subjects…
-
Everest Medicines’ Xerava NDA Accepted by Taiwan’s TFDA
•
Everest Medicines (HKG: 1952) announced that its New Drug Application (NDA) for Xerava (eravacycline) for the treatment of complicated intra – abdominal infections (cIAI) has been accepted for review by the Taiwan Food and Drug Administration (TFDA). Partnership DetailsThe China-based biopharma also entered into an exclusive partnership agreement with TTY…
-
China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the first half of 2022, ending June 30. The company reported revenues of HKD5.212 billion (USD664 million), marking a 14.1% year-on-year (YOY) increase. Excluding income from changes in fair value relating to the investment in Telix,…
